Stocktoria
ABEONA THERAPEUTICS INC. ABEO
ABEONA THERAPEUTICS INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | — | $3.5M | $1.4M | $3.0M | $10.0M | — | $3.0M | $837,000 | $889,000 |
| R&D expense | $26.8M | $34.4M | $31.1M | $29.0M | $38.7M | $30.1M | $48.6M | $38.7M | $17.0M | $10.7M |
| SG&A expense | $65.0M | $29.9M | — | — | — | — | — | — | — | — |
| Operating income | -$89.4M | -$64.2M | -$47.1M | -$50.9M | -$89.8M | -$81.4M | -$77.1M | -$58.2M | -$27.8M | -$23.9M |
| Interest expense | $3.7M | $4.2M | $418,000 | $736,000 | $3.7M | $4.1M | — | — | — | — |
| Income tax | $100,000 | — | — | — | — | — | — | $0 | $0 | $0 |
| Net income | $71.2M | -$63.7M | -$54.2M | -$39.7M | -$84.9M | -$84.2M | -$76.3M | -$56.7M | -$27.3M | -$21.9M |
| EPS (diluted) | $1.01 | $-1.55 | $-2.53 | $-5.53 | — | — | — | — | — | — |
| Operating cash flow | -$76.3M | -$56.0M | -$37.0M | -$43.5M | -$65.7M | -$35.0M | -$62.8M | -$39.1M | -$22.7M | -$13.0M |
| Free cash flow | -$84.3M | -$58.5M | -$37.3M | -$43.6M | -$69.8M | -$36.4M | -$69.1M | -$48.4M | -$23.5M | -$13.5M |
| Cash & equivalents | $78.4M | $23.4M | $14.5M | $14.2M | $32.9M | $12.6M | $129.3M | $18.8M | $137.8M | $69.1M |
| Inventory | $5.5M | — | — | — | — | — | — | — | — | — |
| Total assets | $219.6M | $108.9M | $64.0M | $64.2M | $79.6M | $151.2M | $223.4M | $174.4M | $178.8M | $111.1M |
| Total liabilities | $60.4M | $64.9M | $49.2M | $37.5M | $37.2M | $48.6M | $45.0M | $40.4M | $8.7M | $12.0M |
| Shareholders' equity | $159.2M | $44.0M | $14.8M | $26.8M | $42.4M | $102.6M | $178.4M | $134.0M | $170.1M | $99.1M |
Growth · year-over-year · Revenue CAGR 30.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | +147.5% | -52.9% | -70.0% | — | — | +258.2% | -5.8% | -14.5% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.